Free tool
FAERS Monitor: Signifor Lar Kit
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203255 or its brand name (Signifor Lar Kit, Pasireotide Pamoate). Reports on generic versions are filed under their own applications.
Reports
1,502
Serious
1,066
71% of reports
Hospitalization
452
Death reported
103
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased169
- diabetes mellitus165
- hyperglycaemia163
- drug ineffective125
- diarrhoea121
- off label use120
- headache117
- fatigue105
- nausea97
- dizziness72
- blood pressure increased69
- asthenia60
- vomiting60
- weight decreased58
- glycosylated haemoglobin increased56
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 6 |
| 2014 | 21 |
| 2015 | 60 |
| 2016 | 139 |
| 2017 | 138 |
| 2018 | 138 |
| 2019 | 128 |
| 2020 | 175 |
| 2021 | 96 |
| 2022 | 124 |
| 2023 | 157 |
| 2024 | 136 |
| 2025 | 118 |
| 2026 | 64 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,657 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hyperglycaemiaSignal | 163 | 62.9 | 54.4 | 9,844 |
| glycosylated haemoglobin increasedSignal | 56 | 31.1 | 24.1 | 1,602 |
| diabetes mellitusSignal | 165 | 30.4 | 26.3 | 4,664 |
| blood glucose increasedSignal | 169 | 12.6 | 10.9 | 1,803 |
| blood pressure increasedSignal | 69 | 6.3 | 5.0 | 306 |
| weight decreasedSignal | 58 | 2.9 | 2.3 | 72 |
| diarrhoeaSignal | 121 | 2.6 | 2.2 | 124 |
| headacheSignal | 117 | 2.6 | 2.2 | 118 |
| astheniaSignal | 60 | 2.2 | 1.7 | 40 |
| dizzinessSignal | 72 | 2.0 | 1.6 | 37 |
| off label use | 120 | 1.9 | 1.6 | 54 |
| fatigue | 105 | 1.9 | 1.6 | 45 |
| vomiting | 60 | 1.8 | 1.4 | 20 |
| nausea | 97 | 1.7 | 1.4 | 29 |
| drug ineffective | 125 | 1.3 | 1.1 | 10 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.